Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer

Oncology Research

Volumn 17, Issue 11-12, 2009, Pages 559-564

  Neri, Burno ^a,b   Cipriani, G ^a   Grifoni, R ^a   Molinara, E ^a   Pantaleo, P ^a   Rangan, S ^a   Vannini, A ^a   Tonelli, P ^b   Valeri, A ^b   Pantalone, D ^a   Taddei, A ^a   Bechi, P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Chemotherapy; Gemcitabine; Irinotecan; Pancreatic cancer

Indexed keywords

GEMCITABINE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HUMAN; LUNG DISEASE; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR GROWTH; ADENOCARCINOMA; MIDDLE AGED; MORTALITY; PANCREAS TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 70350505891     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504009789745610     Document Type: Article

References (21)

1. Kelly, D. M.; Benjamin, I. S. Pancreatic carcinoma. Ann. Oncol. 6:19-28; 1995.
2. Niederhuber, J. E.; Brennan, M. F.; Menck, H. R. The national cancer database reports in pancreatic cancer. Cancer 76:1671-1677; 1995.
3. Ferlay, J.; Bray, F.; Pisani, P.; et al. Cancer incidence, mortality and prevalence worldwide, version 1.0. Lyon: IARC Press; 2001.
4. Hawes, R. H.; Xiong, Q.; Waxman, I.; et al. A multispecialty approach to the diagnosis and menagement of pancreatic cancer. Am. J. Gastroenterol. 95:17-31; 2000.
5. Cullinan, S.; Moertel, C. G.; Wieand, H. S.; et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 65:2207-2212; 1990.
6. Schnall, S. F.; Macdonald, J. S. Chemotherapy of adenocarcinoma of the pancreas. Semin. Oncol. 23:220-228; 1996.
7. Lunkettt, W.; Huang, P.; Searcy, C. E.; et al. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin. Oncol. 23:3-15; 1996.
8. van Moorsel, C. J.; Peters, G. J.; Pinedo, H. M. Gemcitabine future prospects of single agent and combination studies. Oncologist 2(3):127-134; 1997.
9. Gottlieb, J. A.; Guarino, A. M.; Call, J. B.; et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 54:461-470; 1970.
10. Rocha Lima, C. M.; Sherman, Ca.; Brescia, F. J.; et al. Irinotecan/ gemcitabine combination chemotherapy in pancreatic cancer. Oncology 15:46-51; 2001.
11. Kanzana, F.; Saijo, N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin. Oncol. 24:7-16; 1997.
12. Bahadori, H. R.; Rocha Lima, C. S.; Green, M. R.; et al. Synergic effect of gemcitabine and irinotecan on brest and small cell lung cancer cell lines. Anticancer Res. 19: 5423-5428; 1999.
13. Caio Max, S.; Rocha Lima, C. M.; Savarese, D.; et al. Irinotecan plus gemcitabine induces both radiographic and Ca 19-9 tumor marker responses in patients with previous untreated advanced pancreatic cancer. J. Clin. Oncol. 20(5):1182-1191; 2002.
14. Stathopoulos, G. P.; Rigatos, S. K.; Dimopoulos, M. A.; et al. Treatment of pancreatic cancer with a combination of irinotecan and gemcitabine: A multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. 14(3):388-394; 2003.
15. Miller, A. B.; Hoogstraten, B.; Staquet, M.; et al. Reporting results of cancer treatment. Cancer 72:207-214; 1981.
16. Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10:1-10; 1989.
17. Kaplan, E.; Meier, P. Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc. 53:457-481; 1958.
18. Lentner, C. Exact confidence limits. In: Geigy scientific tables. Switzerland: Ciba-Geigy; 1982:89-102.
19. Kozuch, P.; Grossbard, M. L.; Barzdins, A.; et al. Irinotecan combined with gemcitabine, 5-fluorouracil, lecovorin and cisplatin (G-FLIP) is an effecitive and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6(6):488-495; 2001.
20. Rocha Lima, C. M.; Green, M. R.; Rotche, R.; et al. Irinptecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with localy advanced or metastatic pancratic cancer despite increased tumor response rate. J. Clin. Oncol. 22(18):3776-3783; 2004.
21. Endlicher, E.; Troppmannm, M.; Kullmann, A.; et al. Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: A phase II study. Oncology 72(69): 279-284; 2008.